Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 700-703

  Martinelli, Ida ^a   Taioli, Emanuela ^b   Bucciarelli, Paolo ^b   Akhavan, Sepideh ^b   Mannucci, Pier Mannuccio ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b NONE

Author keywords

Factor V mutation; Oral contraceptives; Prothrombin mutation; Venous thrombosis

Indexed keywords

ORAL CONTRACEPTIVE AGENT; PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0032976317     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.700     Document Type: Article

References (32)

1. Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369:64-67.
2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
3. Rees DC, Cox M, Clegg JB. Word distribution of factor V Leiden. Lancet. 1995;346:1133-1134.
4. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706-708.
5. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C: Leiden thrombophilia study. Nature. 1994;369:64-67.
6. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thromboembolism in apparently healthy men. N Engl J Med. 1995;332:912-917.
7. Cattaneo M, Chantarangkul V, Taioli E, Hermida Santos J, Tagliabue L. The G20210A mutation of the prothrombin gene in patients with previous first episode of deep-vein thrombosis: prevalence and association with factor V G1691A, methylene tetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res. 1999;93:1-8.
8. Rajesh KK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol. 1997;17:2875-2879.
9. Hillarp A, Zöller B, Svensson PJ, Dählback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 1997;78: 990-992.
10. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol. 1997;98:907-909.
11. Arruda VR, Annichino-Bizzacchi JM, Gonçalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost. 1997;78:1430-1433.
12. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population. Br J Haematol. 1997;98:353-355.
13. 20210 mutation. Thromb Haemost. 1998;79:907-911.
14. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993;342:1503-1506.
15. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344: 1453-1457.
16. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol. 1996;143:1257-1265.
17. Poort SR, Bertina RM, Vos HL. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Haemost. 1997;78: 1157-1158.
18. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost. 1994;72:880-886.
19. Sas G, Pepper DS, Cash JD. Plasma and serum antithrombin III: differentiation by crossed immunoelectrophoresis. Thromb Res. 1975;6:87-91.
20. Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood. 1986;67:504-508.
21. Woolf B. On estimating the relation between blood group and disease. Ann Hum Gen. 1995;19:251-253.
22. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincot-Raven; 1998.
23. Alhenc-Gelas M, Le Cam-Duchez V, Emmerich J, Frebourg T, Fiessinger JN, Borg JY, Aiach M. The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gln mutation in thrombophilic families. Blood. 1997;90:1711.
24. Howard TE, Marusa M, Boisza J, Young A, Sequeira J, Channell C, Guy C, Benson E, Duncan A. The prothrombin gene 3′-untranslated region mutation is frequently associated with factor V Leiden in thrombophilic patients and shows ethnic-specific variation in allele frequency. Blood. 1998;91:1092-1093.
25. Ehrenforth S, Ludwig G, Klinke S, Krause M, Scharrer I, Nowak-Göttl U. The prothrombin 20210 A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrombophilia. Blood. 1998;91:2209-2210.
26. Zöller B, Svensson PJ, Dahlbäck B, Hillarp A. The A 20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood. 1998;91:2210-2211.
27. Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost. 1997;78:327-333.
28. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338: 1793-1797.
29. Kluft C, Lansink M. Effect of oral contraceptives on hemostatic variables. Thromb Haemost. 1997;78:315-326.
30. de Bruijn SFTM, Stam J, Vandenbroucke JP, for the CVST study group. Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives: Central Venous Sinus Thrombosis Study Group. Lancet. 1998;351:1404.
31. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden. should we screen oral contraceptive users and pregnant women? BMJ. 1996;313:1127-1130.
32. Briët E, van der Meer FJM, Rosendaal FR, Houwing-Duistermatt JJ, van Houvwelingen JC. The family history and inherited thrombophilia. Br J Haematol. 1994;87:348-352.